Our ultimate goals are to understand, predict, prevent, and treat anthracycline-induced cardiotoxicity (AIC) in cancer patients receiving Anthracyclines (AC). Within the 5-year plan of this Transatlantic Network of Excellence, we intend to (see Figure): Specific Aim 1. Elucidate the matrix of molecular signals that define the pathophysiology of AIC using in vitro and in vivo mouse models of AIC, hiPSC-CM, human myocardial slices. Specific Aim 2. Identify and validate novel genetic/molecular signaling signatures to develop innovative biomarker strategies to identify patients at high-risk of experiencing AIC, using single cell transcriptome (SC-RNA-Seq) of human biopsy samples, blood samples and hiPSC-CM. Specific Aim 3. Define druggable pathways and provide proof of concept pharmacological strategies for the prevention and treatment of AIC.
|Effective start/end date||1/1/20 → 12/31/24|
- Leducq Foundation (19CVD02)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.